Multiple Sclerosis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Multiple Sclerosis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month7 studies across 5 companies, in the next 180 days.
October 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BIIB | Biogen | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)NCT05925049observationalPercentage of Participants in Natalizumab-Naive and Other MS mAb-Naive Cohort who Start Taking Natalizumab Injections and Develop Anti-Natalizumab Antibodies (ANAs) | — | Active, not recruiting | 2026-10-31 | in 72 d | 2026-05-13 |
| TGTX | TG Therapeutics, Inc. | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkNCT06143514observationalArea Under the Milk Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of BRIUMVI™ | — | Recruiting | 2026-10-31 | in 72 d | 2026-07-20 |
| TGTX | TG Therapeutics, Inc. | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab | Phase 3 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-07-17 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IMUX | Immunic AG | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-02-23 |
| IMUX | Immunic AG | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638To evaluate efficacy of IMU-838 versus placebo based on time to first relapse | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-02-23 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsNCT05811416observationalTime from ozanimod treatment initiation to ozanimod treatment permanent discontinuation | — | Active, not recruiting | 2027-01-20 | in 153 d | 2026-05-29 |
| TCRX | TScan Therapeutics, Inc. | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Jan 2027 | ≤ 164 d | 2025-11-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Multiple Sclerosis
most recently updated first300 studies match. Showing the first 100 of 300 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNY | Sanofi | — | A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuation | Phase 3 | Active, not recruiting | Drug: Tolebrutinib, Placebo, Teriflunomide | Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis | 2,500 | 2024-04-16 | 2029-04-30 | in 984 d | 2026-08-17 |
| SNY | Sanofi | — | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292Area under the curve over the interval W20 to W24(part A) | Phase 3 | Recruiting | Drug: Frexalimab, Frexalimab, MRI contrast-enhancing preparations | Multiple Sclerosis | 160 | 2026-01-14 | 2027-07-15 | in 329 d | 2026-08-14 |
| BIIB | Biogen | $31.4B | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)NCT05658497observationalNumber of Major Congenital Malformations (MCMs) | — | Recruiting | Drug: Diroximel Fumarate, Avonex, Dimethyl Fumarate · Biological: Tysabri | Multiple Sclerosis | 908 | 2023-10-27 | 2032-07-06 | in 2,147 d | 2026-08-11 |
| BMY | Bristol-Myers Squibb | $134.9B | Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to ZeposiaNCT07732907observationalProportion of progressive multifocal leukoencephalopathy (PML) cases by participant characteristics and potential risk factors among ozanimod-exposed participants with multiple sclerosis | — | Recruiting | Drug: Ozanimod | Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy | 15 | 2026-06-04 | 2041-07-31 | in 5,459 d | 2026-07-29 |
| AMGN | Amgen | $229.9B | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)NCT06700343Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP) | Phase 3 | Active, not recruiting | Drug: Ocrelizumab (US), Ocrelizumab (EU), ABP 692 | Relapsing-remitting Multiple Sclerosis (RRMS) | 152 | 2025-01-13 | 2027-04-19 | in 242 d | 2026-07-27 |
| AZN | AstraZeneca | — | An Open-label Study of AZD0120 in Adults With Multiple SclerosisNCT07224373Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS) | Phase 1 | Recruiting | Biological: AZD0120 - Regimen 1, AZD0120 - Regimen 2 | Multiple Sclerosis | 24 | 2025-12-09 | 2028-12-12 | in 845 d | 2026-07-27 |
| SNY | Sanofi | — | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapses | Phase 3 | Active, not recruiting | Drug: Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal | Multiple Sclerosis | 1,655 | 2023-12-13 | 2027-05-06 | in 259 d | 2026-07-20 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkNCT06143514observationalArea Under the Milk Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of BRIUMVI™ | — | Recruiting | Other: No intervention | Relapsing Multiple Sclerosis | 16 | 2024-03-26 | 2026-10-31 | in 72 d | 2026-07-20 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)NCT06433752observationalAnnualized Relapse Rate (ARR) | — | Recruiting | Other: No Intervention | Relapsing Multiple Sclerosis, Multiple Sclerosis | 2,000 | 2024-07-22 | 2032-04-01 | in 2,051 d | 2026-07-20 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)NCT07503873Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab | Phase 2 | Recruiting | Drug: Ublituximab, Ublituximab · Device: Prefilled pen | Multiple Sclerosis | 350 | 2026-04-01 | 2027-05-30 | in 283 d | 2026-07-20 |
| TGTX | TG Therapeutics, Inc. | $7.7B | An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisNCT04130997Annualized Relapse Rate (ARR) | Phase 3 | Active, not recruiting | Biological: Ublituximab | Relapsing Multiple Sclerosis (RMS) | 1,100 | 2019-11-18 | 2032-05-31 | in 2,111 d | 2026-07-17 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabNCT05877963Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 | Phase 3 | Recruiting | Biological: Ublituximab · Drug: Placebo | Relapsing Multiple Sclerosis | 800 | 2023-06-13 | 2027-12-01 | in 468 d | 2026-07-17 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)NCT06433765observationalPercentage of Participants with Major Congenital Malformations (MCMs) | — | Recruiting | Other: No intervention | Multiple Sclerosis | 728 | 2024-06-01 | 2035-03-31 | in 3,145 d | 2026-07-17 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab | Phase 3 | Active, not recruiting | Biological: Ublituximab, Ublituximab | Relapsing Multiple Sclerosis | 360 | 2025-07-09 | 2026-10-31 | in 72 d | 2026-07-17 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisNCT07220252Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab | Phase 2/3 | Recruiting | Drug: Ublituximab, Placebo, Placebo, Fingolimod | Relapsing Multiple Sclerosis | 240 | 2026-07-01 | 2030-01-01 | in 1,230 d | 2026-07-17 |
| CABA | Cabaletta Bio | $493M | RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisNCT07006805Primary (Part A: Dose Escalation) incidence and severity of adverse events | Phase 1/2 | Withdrawnsponsor's stated reason: The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio. | Biological: CABA-201 | Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis | 0 | Jun 2026 | Sep 2028 | ≤ 772 d | 2026-06-25 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsNCT06735248Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2 | Recruiting | Biological: mRNA-1195, Placebo | Multiple Sclerosis | 180 | 2025-04-16 | 2029-01-08 | in 872 d | 2026-06-15 |
| BIIB | Biogen | $31.4B | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNCT05688436observationalNumber of Major Congenital Malformations (MCMs) | — | Active, not recruiting | Drug: Diroximel Fumarate, Fingolimod, Glatiramer acetate, Ozanimod, Ponesimod, Siponimod · Biological: Alemtuzumab, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Peginterferon beta-1a | Multiple Sclerosis | 1,178 | 2021-09-24 | 2031-01-17 | in 1,611 d | 2026-06-04 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsNCT05811416observationalTime from ozanimod treatment initiation to ozanimod treatment permanent discontinuation | — | Active, not recruiting | — | Relapsing-remitting Multiple Sclerosis (RRMS) | 200 | 2023-06-14 | 2027-01-20 | in 153 d | 2026-05-29 |
| BIIB | Biogen | $31.4B | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT02283853results2026-05-19Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans | Phase 3 | Completed | Drug: dimethyl fumarate, Interferon β-1a | Relapsing-Remitting Multiple Sclerosis | 156 | 2014-08-28 | 2025-07-08actual | — | 2026-05-19 |
| SNY | Sanofi | — | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period | Phase 3 | Active, not recruiting | Drug: Frexalimab, Placebo, MRI contrast-enhancing agents | Multiple Sclerosis | 943 | 2023-12-27 | 2028-03-24 | in 582 d | 2026-05-14 |
| BIIB | Biogen | $31.4B | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)NCT05925049observationalPercentage of Participants in Natalizumab-Naive and Other MS mAb-Naive Cohort who Start Taking Natalizumab Injections and Develop Anti-Natalizumab Antibodies (ANAs) | — | Active, not recruiting | Drug: Natalizumab | Multiple Sclerosis | 400 | 2023-06-30 | 2026-10-31 | in 72 d | 2026-05-13 |
| BMY | Bristol-Myers Squibb | $134.9B | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisNCT06408259Annualized relapse rate (ARR) | Phase 3 | Recruiting | Drug: Ozanimod, Fingolimod · Other: Placebo | Multiple Sclerosis, Relapsing-Remitting | 194 | 2025-04-08 | 2031-04-11 | in 1,695 d | 2026-04-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3541860 in Adult Participants With Relapsing Multiple SclerosisNCT06220669Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions | Phase 2 | Active, not recruiting | Drug: LY3541860, Placebo | Multiple Sclerosis | 63 | 2024-03-19 | 2025-10-18actual | — | 2026-04-07 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)NCT07483632TP Cohort A and OLE Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation | Phase 3 | Not yet recruiting | Drug: Diroximel Fumarate, Dimethyl Fumarate, Fingolimod, Placebo matching DRF, Placebo matching DMF, Placebo matching fingolimod | Relapsing Forms of Multiple Sclerosis | 185 | 2026-11-16 | 2034-07-28 | in 2,899 d | 2026-03-19 |
| IMUX | Immunic AG | $2.6B | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse | Phase 3 | Active, not recruiting | Drug: IMU-838 tablets, Placebo matching IMU-838 tablets | Multiple Sclerosis | 1,121 | 2021-11-18 | Nov 2026 | ≤ 102 d | 2026-02-23 |
| IMUX | Immunic AG | $2.6B | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638To evaluate efficacy of IMU-838 versus placebo based on time to first relapse | Phase 3 | Active, not recruiting | Drug: IMU-838 tablets, Placebo matching IMU-838 tablets | Multiple Sclerosis, Relapsing-Remitting | 1,100 | 2022-01-12 | Nov 2026 | ≤ 102 d | 2026-02-23 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)NCT05798520Part 1: Number of Participants With Adverse Events (AEs) | Phase 2 | Completed | Drug: BIIB091, DRF, Placebo | Relapsing Forms of Multiple Sclerosis | 127 | 2023-07-25 | 2026-02-10actual | — | 2026-02-20 |
| KYTX | Kyverna Therapeutics | $526M | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101NCT07403188observationalNumber of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | — | Recruiting | Drug: KYV-101 | Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc) | 70 | 2025-11-24 | Jan 2041 | ≤ 5,278 d | 2026-02-11 |
| SNY | Sanofi | — | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)NCT044580516-month composite Confirmed Disability Progression (cCDP) | Phase 3 | Completed | Drug: Tolebrutinib, Placebo | Primary Progressive Multiple Sclerosis | 767 | 2020-08-13 | 2025-11-14actual | — | 2026-01-07 |
| BIIB | Biogen | $31.4B | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple SclerosisNCT05265728results2025-11-25Part 1: Cumulative Number of New Active Lesions up to Week 24 Identified Using Brain Magnetic Resonance Imaging (MRI) Scans | Phase 3 | Terminatedsponsor's stated reason: Due to sponsor decision, not for efficacy or safety reasons. | Drug: Natalizumab | Multiple Sclerosis, Relapsing-Remitting | 21 | 2022-04-26 | 2024-01-18actual | — | 2025-11-25 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Procedure: Companion blood samples with procedure | Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis | 300 | 2023-01-03 | Jan 2027 | ≤ 164 d | 2025-11-24 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their OffspringNCT05170126observationalMajor congenital malformations | — | Recruiting | — | Multiple Sclerosis | 1,182 | 2022-07-15 | 2032-06-30 | in 2,141 d | 2025-11-20 |
| BIIB | Biogen | $31.4B | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)NCT05083923results2025-10-24Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Phase 3 | Completed | Drug: Diroximel fumarate | Relapsing Forms of Multiple Sclerosis | 136 | 2021-11-18 | 2024-09-11actual | — | 2025-10-24 |
| SNY | Sanofi | — | Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisNCT03996291results2025-10-23Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Phase 2 | Completed | Drug: Tolebrutinib | Relapsing Multiple Sclerosis | 125 | 2019-09-23 | 2024-11-26actual | — | 2025-10-23 |
| BIIB | Biogen | $31.4B | A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)NCT05767736observationalNumber of Participants With Confirmed Serious Adverse Events (SAEs) in the Vumerity, Tecfidera, Other Selected DMTs (Teriflunomide, Beta-interferons, or Glatiramer Acetate), or Vumerity/Tecfidera Switch Cohorts | — | Active, not recruiting | Drug: Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) | Multiple Sclerosis | 10,500 | 2024-06-08 | 2032-12-01 | in 2,295 d | 2025-10-16 |
| SNY | Sanofi | — | A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple SclerosisNCT05630547results2025-10-15Part A: Change From Baseline to Week 48 in Serum Neurofilament Light Chain (sNfL) Levels | Phase 2 | Terminatedsponsor's stated reason: The study was terminated as it did not meet its primary and key secondary endpoints | Drug: SAR443820 · Other: Placebo | Multiple Sclerosis | 174 | 2022-12-19 | 2024-11-21actual | — | 2025-10-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT05658601observationalReason for switching treatment | — | Completed | — | Multiple Sclerosis, Relapsing-Remitting | 104 | 2023-07-14 | 2025-07-03actual | — | 2025-10-01 |
| SNY | Sanofi | — | Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisNCT04879628results2025-09-30Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI) | Phase 2 | Active, not recruiting | Drug: SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations | Multiple Sclerosis | 129 | 2021-06-07 | 2022-09-21actual | — | 2025-09-30 |
| SNY | Sanofi | — | Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 WeeksNCT04410965PK exposure: Cmax | Phase 4 | Completed | Drug: TERIFLUNOMIDE | Multiple Sclerosis | 82 | 2020-05-20 | 2021-07-12actual | — | 2025-09-24 |
| SNY | Sanofi | — | Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsNCT04171310Percentage of radioactive dose excreted in urine and feces | Phase 1 | Completed | Drug: SAR442168 | Multiple Sclerosis | 6 | 2019-11-13 | 2019-12-30actual | — | 2025-09-23 |
| SNY | Sanofi | — | Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisNCT03889639results2023-03-08Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions | Phase 2 | Completed | Drug: SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) | Relapsing Multiple Sclerosis | 130 | 2019-03-29 | 2020-01-02actual | — | 2025-09-17 |
| SNY | Sanofi | — | Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult SubjectsNCT06064539Pharmacokinetics: AUClast of SAR442168 | Phase 1 | Completed | Drug: Tolebrutinib, gemfibrozil, rifampicin | Multiple Sclerosis | 30 | 2020-05-18 | 2020-07-08actual | — | 2025-09-17 |
| BIIB | Biogen | $31.4B | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877Part 1: Annualized Relapse Rate (ARR) at Week 48 | Phase 3 | Active, not recruiting | Drug: BIIB017 (peginterferon beta-1a), Interferon beta type 1a | Multiple Sclerosis, Relapsing-Remitting | 152 | 2019-10-18 | 2027-05-20 | in 273 d | 2025-09-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)NCT05335031observationalProportion of participants persistence with therapy | — | Completed | Drug: Ozanimod | Multiple Sclerosis, Relapsing-Remitting | 450 | 2021-03-03 | 2025-06-30actual | — | 2025-09-08 |
| CTNM | Contineum Therapeutics | $335M | PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPFNCT06683612LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan. | Phase 1 | Completed | Drug: PIPE-791 | Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Progressive, Multiple Sclerosis, Secondary Progressive, Healthy, Healthy Volunteers | 16 | 2024-12-09 | 2025-06-04actual | — | 2025-08-06 |
| SNY | Sanofi | — | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)NCT04410978results2025-06-18Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses | Phase 3 | Completed | Drug: Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide | Relapsing Multiple Sclerosis | 974 | 2020-06-30 | 2024-07-15actual | — | 2025-07-02 |
| SNY | Sanofi | — | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)NCT04410991results2025-06-18Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses | Phase 3 | Completed | Drug: Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide | Relapsing Multiple Sclerosis | 899 | 2020-06-11 | 2024-07-16actual | — | 2025-07-02 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyNCT05605782observationalIncidence of major adverse cardiovascular events (MACE) | — | Active, not recruiting | — | Multiple Sclerosis, Relapsing-Remitting | 9,000 | 2021-09-02 | 2033-07-26 | in 2,532 d | 2025-06-26 |
| BIIB | Biogen | $31.4B | A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaNCT05658484Annualized Relapse Rate (ARR) | Phase 4 | Completed | Drug: Dimethyl fumarate | Multiple Sclerosis | 60 | 2023-06-09 | 2025-03-27actual | — | 2025-05-16 |
| BIIB | Biogen | $31.4B | TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated ParticipantsNCT05236777observationalNumber of Participants With Progressive Multifocal Leukoencephalopathy (PML) who are Taking Natalizumab | — | Completed | Drug: Natalizumab | Multiple Sclerosis | 675 | 2019-01-01 | 2025-04-30actual | — | 2025-05-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple SclerosisNCT05064436results2025-04-24Number of Participants With Adverse Events Based on Severity. | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: 11C-BMS-986196 | Multiple Sclerosis (MS) | 10 | 2021-12-10 | 2023-12-18actual | — | 2025-04-24 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisNCT06396039Annualized relapse rate (ARR) over 36 months | Phase 4 | Active, not recruiting | Drug: BMS-986374 | Relapsing Multiple Sclerosis | 84 | 2024-05-15 | 2028-12-29 | in 862 d | 2025-04-16 |
| GAIA | Gaia AG | $36M | Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)NCT06090305Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HALEMS) | Not applicable | Completed | Behavioral: levidex, Control · Other: treatment as usual (TAU) | Multiple Sclerosis | 470 | 2023-11-20 | 2024-12-06actual | — | 2025-01-30 |
| KYTX | Kyverna Therapeutics | $526M | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976To evaluate efficacy of KYV-101 | Phase 2 | Active, not recruiting | Biological: KYV-101 · Drug: Standard lymphodepletion regimen, Anti-CD20 mAB | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS | 120 | 2024-09-20 | Apr 2027 | ≤ 253 d | 2025-01-13 |
| BIIB | Biogen | $31.4B | A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsNCT06127095observationalNumber of Participants who Perceived the Treatment Added Value of Natalizumab Assessed by Likert's Scale | — | Completed | — | Multiple Sclerosis, Relapsing-Remitting | 474 | 2023-11-24 | 2024-11-28actual | — | 2024-12-18 |
| 4503.T | Astellas Pharma Inc | $26.0B | Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple SclerosisNCT00629642Change from baseline in maximum cystometric capacity | Phase 4 | Completed | Drug: Solifenacin Succinate, Solifenacin Succinate, Oxybutynin Hydrochloride, Placebo | Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases | 249 | 2008-03-14 | 2011-01-28actual | — | 2024-11-14 |
| NVS | Novartis | — | Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple SclerosisNCT06644638observationalNumber of Patients Persistent on Ofatumumab and Self-injectable Disease-modifying Therapies (DMTs) | — | Completed | — | Multiple Sclerosis | 3,632 | 2023-02-15 | 2023-10-30actual | — | 2024-10-16 |
| BIIB | Biogen | $31.4B | A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) ParticipantsNCT05701423observationalPercentage of Participants who Develop End of Dose Symptoms (EOD) Under NTZ | — | Terminatedsponsor's stated reason: Due to low enrolment the sponsor decided to terminate the study | Drug: Natalizumab | Multiple Sclerosis | 34 | 2023-02-08 | 2024-07-31actual | — | 2024-09-19 |
| NVS | Novartis | — | A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple SclerosisNCT06588387observationalNumber of Patients by Education Status | — | Completed | — | Secondary Progressive Multiple Sclerosis | 210 | 2022-11-03 | 2023-09-08actual | — | 2024-09-19 |
| NVS | Novartis | — | Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 TherapiesNCT06526000observationalPercentage Change per Year in Immunoglobulin G (IgG) Levels in Patients Receiving Ocrelizumab | — | Completed | — | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 326 | 2022-10-11 | 2024-02-28actual | — | 2024-07-29 |
| BIIB | Biogen | $31.4B | A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT05532163Cumulative Number of Active Lesions (CUALs) Through Week 24 | Phase 4 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Natalizumab | Multiple Sclerosis, Relapsing-Remitting | 1 | 2023-01-23 | 2023-10-09actual | — | 2024-06-21 |
| NVS | Novartis | — | Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying TherapiesNCT06459232observationalNumber of Patients with a Minimum of 6 Months Follow-up by Disease-Modifying Therapy (DMT) Use | — | Completed | — | Multiple Sclerosis | 143 | 2020-11-19 | 2021-12-17actual | — | 2024-06-14 |
| BIIB | Biogen | $31.4B | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationNCT03689972results2024-06-12Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 | Phase 3 | Completed | Drug: Natalizumab, Natalizumab | Multiple Sclerosis, Relapsing-Remitting | 585 | 2018-11-27 | 2023-01-31actual | — | 2024-06-12 |
| BIIB | Biogen | $31.4B | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aNCT00771043Changes in average RNFL thickness as measured by OCT of affected eyes across treatment groups. | Phase 4 | Withdrawnsponsor's stated reason: Sponsor decision to withdraw study at this time. | Drug: TYSABRI and AVONEX | Relapsing-remitting Multiple Sclerosis | 0 | 2008-11-01 | 2009-08-01 | — | 2024-06-03 |
| BIIB | Biogen | $31.4B | Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsNCT01706107observationalChange from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) | — | Terminatedsponsor's stated reason: Due to on-going enrollment challenges | — | Relapsing-Remitting Multiple Sclerosis | 73 | 2012-11-07 | 2015-10-02actual | — | 2024-06-03 |
| BIIB | Biogen | $31.4B | Natalizumab Subcutaneous Immunogenicity and Safety StudyNCT02142192Proportion of participants with persistent anti-natalizumab antibodies | Phase 2 | Terminatedsponsor's stated reason: Sponsor's decision. | Drug: natalizumab | Relapsing Multiple Sclerosis | 2 | 2014-12-01 | 2015-06-04actual | — | 2024-06-03 |
| 068270.KS | Celltrion | $30.7B | A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisNCT05906992Area under the concentration-time curve in PK group | Phase 3 | Recruiting | Biological: CT-P53, US-Ocrevus, EU-Ocrevus | Relapsing-remitting Multiple Sclerosis | 512 | 2024-01-11 | Feb 2027 | ≤ 192 d | 2024-05-22 |
| BIIB | Biogen | $31.4B | A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue DamageNCT05106465observationalCorrelation Between Konectom Tests and MRI Measures of Brain Tissue Damage | — | Completed | Device: Konectom platform | Multiple Sclerosis (MS) | 200 | 2021-12-15 | 2024-04-03actual | — | 2024-05-17 |
| BIIB | Biogen | $31.4B | A Study for Tysabri Participant PreferenceNCT05304520observationalNumber of Participants by Their Preferred Method of Natalizumab Administration at Month 6 | — | Completed | Drug: Natalizumab | Relapsing-Remitting Multiple Sclerosis (RRMS) | 318 | 2021-10-12 | 2024-04-30actual | — | 2024-05-17 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisNCT04203498results2024-05-08Change in Average Daily Spasm Count From Baseline to Week 12 By 4-Week Period During the 12-Week Randomized Period | Phase 3 | Terminatedsponsor's stated reason: This study was terminated based on a business decision by the Sponsor. | Drug: Nabiximols, Placebo | Multiple Sclerosis (MS) | 139 | 2020-10-01 | 2023-02-10actual | — | 2024-05-08 |
| NVS | Novartis | — | A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple SclerosisNCT06395909observationalAnnualized Relapse Rate (ARR) | — | Completed | — | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 113 | 2023-04-23 | 2023-08-31actual | — | 2024-05-02 |
| IMUX | Immunic AG | $2.6B | Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisNCT05054140Efficacy of IMU-838 versus placebo | Phase 2 | Unknown status | Drug: IMU-838, Placebo matching IMU-838 | Multiple Sclerosis | 450 | 2021-09-30 | 2025-01-07 | — | 2024-04-29 |
| IMUX | Immunic AG | $2.6B | MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219results2021-07-23Difference Between 45 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI Lesions | Phase 2 | Active, not recruiting | Drug: IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo, IMU-838 (10 mg/day) | Relapsing-Remitting Multiple Sclerosis (RRMS) | 210 | 2019-01-28 | 2020-04-24actual | — | 2024-04-24 |
| BIIB | Biogen | $31.4B | Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination StudyNCT05197699observationalNumber of Participants who Developed an Immune Response to Their Last SARS-CoV-2-Vaccination | — | Terminatedsponsor's stated reason: Sponsor's decision | — | Multiple Sclerosis (MS) | 160 | 2021-07-01 | 2023-09-30actual | — | 2024-04-17 |
| BIIB | Biogen | $31.4B | Tysabri Observational ProgramNCT00493298observationalNumber of Participants with Serious Adverse Events (SAE) | — | Completed | Drug: Tysabri | Relapsing-Remitting Multiple Sclerosis | 6,620 | 2007-06-29 | 2023-11-01actual | — | 2024-04-08 |
| IPN.PA | Ipsen | $15.5B | Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisNCT00276341Evolution of Paced Auditory Serial Addition Test 3 and 2 seconds between baseline and week 24 | Phase 3 | Completed | Drug: EGb 761® (Tanakan®) | Multiple Sclerosis, Relapsing-Remitting | 47 | 2003-08-26 | — | — | 2024-03-07 |
| ATRA | Atara Biotherapeutics | $88M | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisNCT03283826Part 1: Incidence of adverse events | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated as primary endpoint was not achieved | Biological: ATA188 · Drug: Placebo | Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 134 | 2017-10-19 | 2023-11-09actual | — | 2024-02-23 |
| CTNM | Contineum Therapeutics | $335M | Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy VolunteersNCT05983939Safety: Treatment-Emergent Adverse Events (TEAE) | Phase 1 | Completed | Drug: PIPE-791, Placebo | Multiple Sclerosis | 56 | 2023-06-26 | 2024-02-01actual | — | 2024-02-14 |
| BIIB | Biogen | $31.4B | Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsNCT04832399observationalOverall Disease-Free Status at Month 12 | — | Completed | Drug: Natalizumab | Relapsing Remitting Multiple Sclerosis | 60 | 2013-11-12 | 2023-10-02actual | — | 2024-02-05 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple SclerosisNCT03737851results2023-12-22Mean Overall Response Score (ORS) at Week 52 | Phase 2 | Completed | Drug: elezanumab, placebo | Multiple Sclerosis (MS) | 208 | 2018-12-11 | 2021-08-09actual | — | 2023-12-22 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple SclerosisNCT03737812results2023-12-21Mean Overall Response Score (ORS) | Phase 2 | Completed | Drug: elezanumab, placebo | Multiple Sclerosis (MS) | 123 | 2019-02-27 | 2021-01-15actual | — | 2023-12-21 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their InfantsNCT06133049observationalPrevalence of major congenital malformations among infants | — | Active, not recruiting | Drug: Ozanimod, Select DMTs other than ozanimod, No DMTs | Multiple Sclerosis | 2,961 | 2021-03-16 | 2031-03-31 | in 1,684 d | 2023-11-15 |
| SNY | Sanofi | — | Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult ParticipantsNCT06106074Part 1a and Part 2: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: Tolebrutinib, Placebo | Multiple Sclerosis | 71 | 2020-08-10 | 2022-05-23actual | — | 2023-10-30 |
| BIIB | Biogen | $31.4B | Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by TecfideraNCT04756687observationalTime to ALC Reconstitution After DMF Discontinuation | — | Completed | Drug: Dimethyl fumarate | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 1,507 | 2021-03-10 | 2021-06-15actual | — | 2023-10-23 |
| BIIB | Biogen | $31.4B | Plegridy Satisfaction Study in ParticipantsNCT02587065results2020-01-13Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12 | Phase 4 | Completed | Drug: peginterferon beta-1a | Relapsing-Remitting Multiple Sclerosis (RRMS) | 193 | 2016-02-03 | 2017-10-02actual | — | 2023-08-31 |
| BIIB | Biogen | $31.4B | Efficacy and Safety of BG00012 in MSNCT00168701The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24. | Phase 2 | Completed | Drug: BG00012 | Multiple Sclerosis | 260 | 2004-10-01 | 2006-03-31actual | — | 2023-08-28 |
| SNY | Sanofi | — | An Observational Study on Teriflunomide-exposed PregnanciesNCT03198351observationalRate of major structural defects in live born infants | — | Completed | Drug: Teriflunomide (HMR1726) | Multiple Sclerosis | 220 | 2013-04-25 | 2023-06-13actual | — | 2023-08-28 |
| BIIB | Biogen | $31.4B | Evaluation of Natalizumab for thE Relief of MS Associated FatiGueNCT00464074observationalVisual Analog Scale for Fatigue (VAS-F) | — | Completed | — | Multiple Sclerosis | 89 | 2007-08-01 | 2010-07-31actual | — | 2023-08-22 |
| BIIB | Biogen | $31.4B | Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEPNCT04221191observationalPercentage of Participants with Oral Dimethyl Fumarate (DMF) Persistence at 6 Months | — | Completed | Drug: Dimethyl Fumarate · Other: PSP | Multiple Sclerosis, Relapsing-Remitting | 353 | 2019-08-19 | 2022-09-14actual | — | 2023-08-01 |
| BIIB | Biogen | $31.4B | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsNCT03870763results2023-05-16Time to First Relapse | Phase 3 | Terminatedsponsor's stated reason: Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns. | Drug: Dimethyl Fumarate, Peginterferon Beta-1a, Placebo | Multiple Sclerosis, Relapsing-Remitting | 11 | 2019-03-19 | 2022-07-21actual | — | 2023-06-15 |
| BIIB | Biogen | $31.4B | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)NCT04079088Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 2 | Withdrawnsponsor's stated reason: Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety concerns. | Drug: Placebo, BIIB061, Glatiramer acetate · Biological: Interferon-beta1 | Relapsing Multiple Sclerosis | 0 | 2021-06-30 | 2024-09-18 | — | 2023-06-01 |
| BIIB | Biogen | $31.4B | Dimethyl Fumarate (DMF) Observational StudyNCT02047097observationalThe number of participants that experience Adverse Events (AEs) that lead to discontinuation of dimethyl fumarate (DMF) | — | Completed | Drug: dimethyl fumarate | Multiple Sclerosis | 5,487 | 2013-11-19 | 2022-10-31actual | — | 2023-05-24 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)NCT00681538results2011-12-07The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). | Phase 3 | Completed | Drug: Sativex®, Placebo | Spasticity, Multiple Sclerosis | 572 | Jan 2008 | Jan 2009actual | — | 2023-05-06 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple SclerosisNCT00702468results2011-06-17Number of Subjects Who Experience Treatment Failure. | Phase 3 | Completed | Drug: Sativex, Placebo | Spasticity, Multiple Sclerosis | 36 | Nov 2007 | Jan 2009actual | — | 2023-05-06 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.NCT00711646results2012-09-14Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score. | Phase 3 | Completed | Drug: Sativex®, Placebo | Spasticity, Multiple Sclerosis | 189 | Jun 2002 | Mar 2004actual | — | 2023-05-06 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of the Long-term Safety of Sativex UseNCT01606137results2012-08-23Incidence of Adverse Events as a Measure of Subject Safety. | Phase 3 | Completed | Drug: GW-1000-02 | Multiple Sclerosis, Spasticity, Pain | 507 | Feb 2002 | Dec 2004actual | — | 2023-05-06 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple SclerosisNCT00678795results2012-09-21Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment | Phase 3 | Completed | Drug: Sativex®, Placebo | Detrusor Overactivity, Multiple Sclerosis | 135 | Aug 2002 | Oct 2005actual | — | 2023-05-03 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisNCT01599234results2012-08-16Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment) | Phase 3 | Completed | Drug: Sativex, Placebo | Multiple Sclerosis | 337 | Mar 2005 | Dec 2005actual | — | 2023-05-03 |
| SNY | Sanofi | — | To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisNCT03856619Adverse events (AEs) | Phase 4 | Completed | Drug: TERIFLUNOMIDE HMR1726 | Relapsing Multiple Sclerosis | 121 | 2019-03-27 | 2022-05-13actual | — | 2023-04-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Multiple Sclerosis is matched — 14 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Relapsing Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Relapsing Forms of Multiple Sclerosis
- Multiple Sclerosis (MS)
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Relapsing Multiple Sclerosis (RMS)
- Primary Progressive Multiple Sclerosis
- Progressive Multiple Sclerosis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Multiple Sclerosis” (a text search, wider than this page)